SCHEMBL27162293

SCHEMBL27162293

CC(C)(C)CCN1CCCC2(CCN(S(=O)(=O)c3ccc(N4CCC(F)(F)CC4)nc3)CC2)C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ CYP3A4 P08684 8/20 0.45
▸ TSHR P16473 6/20 0.45
▸ CYP2C19 P33261 5/20 0.45
▸ USP2 O75604 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 6/20 0.42
▸ CYP2D6 P10635 6/20 0.42
▸ CYP1A2 P05177 4/20 0.42
▸ CYP2C9 P11712 3/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27161915 0.91 GAA (0.47) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL27162133 0.91 GAA (0.48) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL27162113 0.90 GAA (0.45) GAAKDM4EUSP2SMN1; SMN2ALDH1A1
SCHEMBL27162351 0.90 GAA (0.48) GAAKDM4ETSHRUSP2SMN1; SMN2
SCHEMBL27161957 0.89 ALDH1A1 (0.56) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL30048847 0.89 ALDH1A1 (0.56) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL27161574 0.89 CYP3A4 (0.51) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL30049987 0.87 GAA (0.43) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL27161879 0.87 GAA (0.43) GAAKDM4ECYP3A4TSHRCYP2C19
SCHEMBL30050587 0.83 CYP3A4 (0.42) GAAKDM4ECYP3A4TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 GAA 3700/4885KDM4E 3959/4885CYP3A4 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback